Pacira BioSciences (PCRX) CEO logs 41,488-share tax withholding on RSU vesting

Rhea-AI Filing Summary

Pacira BioSciences, Inc. CEO Lee Frank D. reported an automatic share withholding related to equity compensation. On January 30, 2026, 41,488 shares of common stock were withheld by Pacira at $20.54 per share to cover tax obligations on a vested restricted stock unit award.

After this tax withholding, Lee Frank D. directly beneficially owned 399,012.841 shares of Pacira common stock. The transaction reflects routine administration of equity compensation rather than an open-market trade.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lee Frank D.

(Last) (First) (Middle)

C/O PACIRA BIOSCIENCES, INC.

2000 SIERRA POINT PARKWAY, SUTE 900

(Street)

BRISBANE CA 94005

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Pacira BioSciences, Inc. [ PCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/30/2026		F		41,488(1)	D	$20.54	399,012.841	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award.

Remarks:

	/s/ Kristen Williams, Attorney-in-Fact	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Pacira BioSciences (PCRX) report for its CEO?

Pacira BioSciences reported that CEO Lee Frank D. had 41,488 common shares withheld on January 30, 2026. These shares were withheld by the company to satisfy tax obligations arising from the vesting of a restricted stock unit award, rather than from an open-market sale.

At what price were Pacira BioSciences (PCRX) shares withheld in the CEO’s Form 4?

The 41,488 Pacira common shares related to the CEO’s tax withholding were valued at $20.54 per share. This reflects the price used for the share withholding tied to the vesting of a restricted stock unit award, as disclosed in the Form 4 filing.

How many Pacira BioSciences (PCRX) shares does the CEO own after this transaction?

Following the January 30, 2026 tax-withholding transaction, CEO Lee Frank D. directly beneficially owned 399,012.841 shares of Pacira common stock. This figure reflects his remaining direct holdings after 41,488 shares were withheld to cover tax obligations on a vested RSU award.

What does transaction code ‘F’ mean in the Pacira (PCRX) CEO’s Form 4 filing?

Transaction code “F” in the CEO’s Form 4 indicates shares were withheld by the issuer to pay tax withholding obligations. In this case, 41,488 Pacira common shares were automatically withheld in connection with the vesting of a restricted stock unit award granted to the CEO.

Was the Pacira (PCRX) CEO’s Form 4 transaction an open-market sale of shares?

No, the transaction was not an open-market sale. The Form 4 explains that 41,488 shares were withheld by Pacira to cover tax withholding obligations triggered by the vesting of a restricted stock unit award granted to CEO Lee Frank D.

What role does Lee Frank D. hold at Pacira BioSciences (PCRX) in this Form 4?

In this Form 4, Lee Frank D. is identified as both a director and the Chief Executive Officer of Pacira BioSciences, Inc. The reported transaction relates to his equity compensation, specifically tax withholding on a vested restricted stock unit award.